



EANO

EUROPEAN ASSOCIATION
OF NEURO-ONCOLOGY

ANNUAL REPORT 2015

Content

Preface	2
EANO Executive Board 2014-2016	2
Scientific Committee.	2
Report from the Istanbul Meeting, 4th EORTC-EANO-ESMO 2015 Conference.....	3
Guidelines	3
WFNOS Magazine.....	4
Awards 2015	4
Outlook on Heidelberg.....	5
EANO matters	5
Upcoming Events	7
Vienna Medical Academy.....	7
Thanks to our Sponsors.....	8

Preface

Dear members of the European Association of Neuro-Oncology, dear colleagues and friends,
It is our great pleasure to present to you the first Annual Report of the European Association of Neuro-Oncology. We would like to inform our membership about our activities and about important developments in Neuro-Oncology in Europe.

On March 27-28, EANO coorganized so far the last biennial Educational Meeting together with the European Society for Medical Oncology (ESMO) and with the Brain Tumor Group of the European Organization for Research and Treatment of Cancer (EORTC) in Istanbul, Turkey.

In late 2015, EANO launched the last issue of the EANO magazine. From 2016 onwards, a new World Federation of Neuro-Oncology Societies (WFNOS) magazine shall be published jointly with our colleagues and friends from the Society for Neuro-Oncology (SNO) in the US; moreover, we hope for participation of the Asian Society for Neuro-Oncology (ASNO) in the near future, too.

Meanwhile, WFNOS has evolved in 2015. We confirm our invitation to all multidisciplinary national Neuro-oncology societies worldwide to join WFNOS as outlined at: www.wfnos.com We are proud that Austria, Belgium, China, Egypt, France, Germany, India, Italy, Japan, Netherlands, South Korea, Spain, Switzerland, Turkey and the United Kingdom, as well as the Society for Neuro-Oncology South America (SNOLA), have already joined WFNOS and we believe that WFNOS will provide the best forum to promote the development of our field in all possible directions.

As a further step towards closer cooperation with SNO, EANO has decided to join forces with SNO and Oxford University Press to jointly publish the new journal, Neuro-Oncology Practice. The respective contracts were signed at the SNO Meeting in San Antonio, Texas, in November 2015.

On behalf of the EANO board, I wish to express our gratitude to all colleagues and institutions that have supported EANO and the field of Neuro-Oncology over the last year of 2015.

Sincerely,

Michael Weller, President EANO



We are the EANO Executive Board 2014-2016

Michael Weller, Zurich, Switzerland, President

Riccardo Soffietti, Turin, Italy, Past President

Geoffrey Pilkington, Ryde, United Kingdom, Treasurer

Elizabeth Moyal, Toulouse, France, Board Member

Roger Henriksson, Umea, Sweden, Head of Scientific Committee

Christine Marosi, Vienna, Austria, Board Member


Guido Reifenberger, Düsseldorf, Germany, Board Member

Martin Taphoorn, The Hague, Netherlands, Board Member

Colin Watts, Cambridge, United Kingdom, Board Member

Ingela Oberg, Cambridge, United Kingdom, Nurse Board Member

Wolfgang Wick, Heidelberg, Germany, Coopted Board Member & EORTC Brain Tumor Group & Host, EANO 2016 Heidelberg



M. Weller

R. Soffietti

G. Pilkington

E. Moyal

R. Henriksson

C. Marosi

G. Reifenberger

M. Taphoorn

C. Watts

I. Oberg

W. Wick

We are supported by the Scientific Committee

Carmen Balaña Quintero, Barcelona, Spain

Anthony Chalmers, Glasgow, United Kingdom

Hugues Duffau, Montpellier, France

Didier Frappaz, Lyon, France

Alan Jackson, Manchester, United Kingdom

Silvia Marino, London United Kingdom

Stefan Oberndorfer, Vienna, Austria

Karin Piil, Copenhagen, Denmark

Zvi Ram, Tel Aviv, Israel

Patrick Roth, Zurich, Switzerland

Roberta Rudà, Turin, Italy



Report from the Istanbul Meeting, 4th EORTC-EANO-ESMO 2015 Conference

The Fourth EORTC-EANO-ESMO 2015 Conference : “Trends in Central Nervous System Malignancies” was organized in Istanbul, Turkey on 27-28 March 2015, also on behalf of the Turkish Neuro-Oncology Society. The conference attracted 335 participants from over 46 different countries, and fellowship grants were awarded to 3 physicians from Russia, Albania and Israel, respectively. Through a series of plenary sessions, workshops and breakout sessions the conference provided an update on novel therapies, agents and combination strategies as well as reports on recent findings in basic and clinical research.

The prognostic and predictive role of molecular diagnostics in the field of neuro-oncology was reviewed also with regard to the upcoming new WHO Classification of Tumors of the Nervous System. The role of the recently discovered TERT and ATRX mutations was discussed, as well as the possibilities of next generation sequencing and the limitations due to the molecular heterogeneity of gliomas. The meeting provided reviews on where we are today in the management of low grade gliomas and 1p/19q co-deleted gliomas, and of glioblastomas in the post AVAGlio era. The emerging role of immunotherapy in glioblastoma was also discussed. Current insights into the management of brain metastasis, neoplastic meningitis and ependymoma were summarized.

Two sessions debated the pros and cons of reirradiation in glioblastoma and stereotactic irradiation to the surgical cavity in brain metastases, respectively. Another session of the conference was devoted to practical issues in neuro-oncology, such as the management of seizures and rehabilitation approaches. Last but not least 98 posters were presented by young researchers.

Overall, this two-day meeting gave a plenty of opportunities to interact and strengthen the links between colleagues from everywhere in Europe and the faculty, all of whom were well-known neuro-oncologists.

R. Soffietti, Turin, Italy

Guidelines

In 2013-2014, EANO decided to develop a new program of Diagnostic and Therapeutic Guidelines in Neuro-Oncology, following a standardized pathway of assembling the guideline task forces, generating the guidelines, and aiming for publication. These guidelines are meant to communicate to our membership a consolidated authentic expert opinion. They are generated without any financial support and are thus fully independent from industry or other potential outside opinion leaders. Compared with guidelines issued by other societies, they have the inherent advantage of being multidisciplinary and hopefully balanced. They will be regularly updated.

Following the publication of the EANO guideline on malignant gliomas in 2014, the first EANO guideline on primary CNS lymphoma was published in 2015.

The first guidelines for brain metastases, meningioma and ependymoma are currently being developed, the revision of the WHO classification will necessitate a new guideline for diffuse gliomas which shall be prepared in 2016.

Together with the RANO PET subcommittee and the European Association for Nuclear Medicine, a guideline on the clinical use of positron emission tomography has been prepared and submitted for publication.

EANO is currently engaging in discussions with SNO and ASNO with regard to potential participation in selected guideline committees. The EANO Board welcomes any suggestions how to improve and further develop our guideline program from our membership.

References

Weller M, Van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W, for the European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO Guideline on the Diagnosis and Treatment of Malignant Glioma. *Lancet Oncol* 2014;15:e395-403

Hoang-Xuan K, Eric Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CMF, Ferreri AJM, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M, for the European Association for Neuro-Oncology (EANO) Task Force on Primary CNS Lymphoma. EANO Guideline for the diagnosis and treatment of primary CNS lymphoma in immunocompetent patients. *Lancet Oncol* 2015;16:e322-332

M. Weller, Zurich, Switzerland

WFNOS Magazine

EANO Magazine => WFNOS Magazine

End of 2014, the EANO Executive Board decided to enlarge the EANO Magazine into a Magazine for all neuro-oncology societies worldwide and therefore to end the cooperation with its former publisher Krause & Pachernegg. The new Magazine intends to form a communication platform for all neuro-oncologists through inter-organizational collaboration. Its purpose is to promote the education of all healthcare professionals involved in Neuro-oncology and to spread news on important developments in Neuro-Oncology from all parts of the world to all parts of the world. The Magazine does not intend to acquire an impact factor. A major scope will also be the organization and promotion for WFNOS meetings.

During 2015 cooperation for the new Magazine between EANO and SNO was started that will later also include ASNO and further neuro-oncology societies. An agreement with Oxford University Press (OUP) as the new publisher has been signed in November 2015.

In 2015, a single issue of the old was issued, still under the name of EANO Magazine, but already with OUP as the publisher. For 2016, three issues are planned. A considerable number of EANO Executive Board members have already agreed to contribute reviews on timely topics

C. Marosi, Vienna, Austria



Awards 2015

EANO Award at ECC2015

The EANO Award is given to scientists who have made an outstanding contribution to the developments in the field of Neuro-Oncology, or to people having greatly contributed to the improvement of patient care at different levels.

Recipient: Jean-Yves Delattre

Jean-Yves Delattre trained in Neurology in Paris, France. He did a Neuro-Oncology fellowship at Memorial Sloan Kettering Cancer Center (New York, NY, USA) with Dr Jerome B. Posner (1985-1988). He was appointed professor of Neurology at the University Pierre and Marie Curie (UPMC), Paris VI in 1992. From 1998 to 2012, he was chairman of the department of Neurology "Mazarin" and head of the laboratory of experimental Neuro-Oncology (Inserm) at the Salpêtrière Hospital, Paris, France. He is currently chief, Pole of Nervous System Diseases (a group of 10 departments of clinical neurosciences) and medical director of the Institute of Translational Neurosciences at the Salpêtrière Hospital (IHU-UPMC). He is past-president of the ANOCEF (French Association of Neuro-Oncologists) and of the EANO (2000-2002). He was on the editorial board of the Journal of Clinical Oncology (Neuro-Oncology section, 2006-2012) and is on the editorial board of "The Oncologist". He is co-author of 335 papers (H index, 62).

JY Delattre contributed to the development of Neuro-Oncology in France and in Europe, particularly through the design, conduct or participation of the "Salpêtrière group" in multicentric trials on gliomas and lymphomas through the ANOCEF and EORTC. He had a special concern for gliomas in the elderly and conducted the randomized trial showing the superiority of radiotherapy over supportive care alone in elderly patients with glioblastoma. As director of the Salpêtrière CNS tumor bank and coordinator of the national network on anaplastic oligodendrogliomas (POLA), he also contributed with his group and others to the study of the natural history of low grade gliomas, to genotype-phenotype correlations in gliomas, particularly the prognostic value of IDH1 mutation and the correlation between molecular profile of gliomas and response to treatment. Finally, as a general Neuro-Oncologist, he participated in several studies on paraneoplastic neurologic syndromes, treatment neurotoxicity and brain metastases.



ECCO Clinical Research Award 2015

Recipient: Martin van den Bent

Martin van den Bent receives the ECCO Clinical Research Award in recognition of his contribution to the integration of translational research and clinical practice in the field of cancer.

After completing his training as a neurologist Martin J. van den Bent joined in 1992 the Neuro-Oncology Unit of Erasmus MC Cancer Center in Rotterdam, Netherlands. With chemotherapy of brain tumours still in its infancy, he developed in the following years a successful program on medical treatment of



primary brain tumours. In 2002 he became the head of the Neuro-Oncology unit, which in 2013 was integrated with the Neurosurgery program on brain tumours into the Brain Tumor Center at Erasmus MC Cancer Center. In 2007 he became professor of Neuro-Oncology at Erasmus University. He has been the principle investigator of a large number of international multicentre phase II and III trials on both high and low grade glial tumours, most of which were conducted through the EORTC Brain Tumour Group. Many of these trials included translational research focusing on the identification of prognostic and predictive molecular parameters of outcome to treatment, and which were key in the establishment of the standard of care of diffuse glioma. After being the EORTC Brain Tumour Group secretary from 1996-2002 he served for 6 years as the chair of this internationally well recognized group. Between 2013 and 2016 he is the chair of the EORTC Clinical Research Division, and he is currently the Treasurer of the EORTC Board. He has established and co-chaired four editions of the bi-annual EORTC-EANO-ESMO educational course on brain tumours, and was between 2001 and 2003 the chair of the Dutch Neuro-Oncology Working group. Prof van den Bent has published widely both on the treatment of primary brain tumours and on neurological complications of systemic cancers. He wrote many chapters in textbooks on neuro-oncology, and is one of the coordinating members of the Response Assessment in Neuro-Oncology (RANO) group revising the endpoints and response criteria of trials in neuro-oncology. Prof van den Bent is married, has three children and one cat.

Outlook on Heidelberg

The Mannheim-Heidelberg area will host the 12th EANO meeting in October 2016. The meeting is held under the auspices of the Neurooncology Working Group of the German Cancer Society (NOA), which together with the local organizers from the International Brain Tumor Center in Heidelberg and the Scientific Committee of EANO grants an outstanding scientific program. Main focus will be put on basic and translational neurooncology in order to shape the concept of modern precision approaches in our field. Complementary, several topics deal with evaluation of patient-centered outcome parameters and all the fascinating developments in diagnostics, but also clinical trials that we have seen in the recent years.

As a novel aspect, EANO will incorporate an international educational day, which is planned and executed together with the EORTC. The educational day brings basic, translational and clinical background for meningioma and glioma including an in depth view on the guidelines and challenges in future trial development. As a topic of increasing relevance, we will devote one session to the generation and understanding of high-throughput data. The meeting will start with a key note lecture on the viral origin of cancer given by Harald zur Hausen, Wednesday night and at that evening, but also in the following days offer plenty of opportunity for scientific exchange and social interaction both in the Rosengarten Center in Mannheim and at the Heidelberg Castle.

W. Wick, Heidelberg, Germany

EANO matters

Travel Grants and Awards 2016

One of the goals of the European Association of Neuro-Oncology is to broaden the network of Neuro-Oncology and to support Neuro-Oncologists in their (inter-) national research projects.

We are proud to be able to offer several grant and award opportunities:

- Travel Grants for EANO Meetings
- Travel Grants for EANO Meetings for nurses
- Travel Award for SNO/ASNO Meeting

EANO Travel Grant for EANO members of less developed countries

EANO encourages the participation of its young members in our meetings and presentation of their work. The EANO Travel Grant facilitates young clinicians and investigators from less developed countries to present an abstract during the EANO Meeting.

Next call for application beginning 2016.

Requirements:

- Young clinicians or basic scientists, trainees and investigators working in the field of Neuro-oncology, born on or after January 1, 1981
- Reference letter from the chairperson of their department to certify that they are in training, as well as a copy of their valid passport and a CV
- EANO Member
- Origin of a less developed country
(due to the data of the worldbank: <http://data.worldbank.org/about/country-and-lending-groups>)



Travel Grant includes:

- Free registration for the EANO 2016 Meeting
- Maximum of EUR 1,000.- for travel and accommodation costs will be refunded after the meeting
- Possibility to present their abstract during the EANO Meeting

EANO Travel Grant for EANO nurse members

EANO is happy to support the participation of Neurooncology nurse members in our meetings. This grant allows active neuro-oncology nurses to attend the EANO congress, in order to present an abstract at the nursing day.

Next call for application beginning 2016.

Requirements:

- Reference letter from the chairperson of their department to certify that as well as a copy of their valid passport and a CV
- EANO Nurse-member

Travel Grant includes:

- Free registration for the EANO 2016 Meeting including the Nurse Day
- Maximum of EUR 1,000.- for travel and accommodation costs will be refunded after the meeting
- Possibility to present their abstract during the EANO Meeting

SNO / ASNO Travel Award of Excellence for EANO members

EANO wishes to support the participation of young EANO members at the international meetings of our partner societies, Society for Neuro-oncology (SNO) and Asian Society for Neuro-oncology (ASNO). This award facilitates young EANO members, who have been selected based on high quality abstracts, to attend the SNO or ASNO congresses.

Next call for application beginning 2016.

Future EANO Meetings call for applications

The EANO Executive Board invites letters of interest to host the EANO meetings in 2019 and 2020. Applicants should be aware that hosting EANO meetings will require major local efforts to prepare the meeting and to secure its funding. Further details may be obtained from the EANO office or the EANO president.

Applicants should submit a letter of interest which

- summarizes the main incentives to host the meeting,
- provide information on the congress venue, and
- indicates the level of support by relevant national societies.

Letters of interest should be submitted by December 31, 2015, to: office@eano.eu

Applications will be reviewed by the EANO Board in January 2016. Shortlisted applications may be invited for personal presentation until or at the EANO 2016 meeting in Heidelberg.

The EANO Board will decide on the venue 2019 directly after the EANO 2016 Meeting in Heidelberg.

Call for EANO Workshop or Symposia apply for financial support/funding

The EANO Executive Board is inviting preliminary, conceptual ideas for short workshops or symposia on any area directly related to the practise of, or research into neuro-oncology. Funds of up to EUR 25.000,- are available for each workshop. Particular emphasis is placed upon career development for medical trainees, nurses, PhD students and early post-doctoral scientists. Host nations from European countries where hosting of major neuro-oncology congresses is precluded, by way of lack of available funding and/or lack of established neuro-oncology infrastructure, are particularly encouraged to apply. EANO will assist with provision of experts within the given area to actively contribute to each workshop.

Initial outline proposals, of not more than 500 words, should be submitted by July 1, 2016 to the EANO Secretariat office@eano.eu.

Applicants will be notified within three months of receipt of this short proposal as to the outcome of their application. Successful preliminary applicants will be required to complete a full application including details on scientific content, dates, location and cost plan. A final selection will be made by December 31, 2016.

Upcoming Events

EANO 2016 Meeting

Register NOW for the EANO 2016 Meeting and save up to € 270,- on registration fees.



**MANNHHEIM/
HEIDELBERG**

OCTOBER 12-16, 2016
12TH MEETING & Educational Day

See you there!

EDUCATIONAL DAY: October 12-13, 2016
- first time in cooperation with the EORTC
- extra programme for nurses

**EUROPEAN ASSOCIATION
OF NEURO-ONCOLOGY**

Congress Center Rosengarten
Mannheim, Germany

www.eano.eu



**WFNOS 2017
ZURICH**

SAVE THE DATE

MAY 4 - 7, 2017
5TH QUADRENNIAL MEETING

**World Federation of
Neuro-Oncology Societies**

Kongresshaus Zürich
Zurich, Switzerland

www.eano.eu

Vienna Medical Academy VMA: who are we and what do we do for EANO?

VMA Association Management

Hello from the EANO Office in Vienna, for those of you who do not know me, my name is Magdalena Mara and since September 2014 I am supporting the Executive Board in all association related administrative matters and projects. Located in the former public hospital of Vienna, the EANO Office is the "communication and control centre" of the association, handling its day to day business. It is the first information point for all EANO related inquiries. All membership communication and support, newsletter and website maintenance, documentation and archiving, accounting and bookkeeping, exhibiting at meetings and congresses and much more is done and steered by the EANO Office. All this is only possible with the fantastic support and input of the EANO Executive Board!

Looking forward to meeting you at the EANO Membership booth in September 2016 in Mannheim/Heidelberg!

VMA Congress Department

Vienna Medical Academy of Postgraduate Medical Education and Research (VMA Ltd.)

The Vienna Medical Academy of Postgraduate Medical Education and Research with its affiliated subsidiary VMA Ltd. is one of Austria's long-standing and leading conference & association management institutions in the field of health care, providing leadership, organisational guidance, headquarters facilities and staff resources to more than 40 medical associations and 30 medical conferences and meetings per year.

Over the past 50 years, the Vienna Medical Academy with its subsidiary VMA Ltd. has provided professional services to more than 1.300 national and international conferences. VMA and VMA Ltd. are dedicated to serve the needs of the medical non-profit sector with a strong commitment to quality, service and value.



S. Wagner*, R. König, K. Ikrath, M. Mara, A. Rosenkranz*
* Conference Manager for EANO Meetings



Last but not least, many thanks to the sponsors of the EANO 2014 Meeting in Turin

SPONSORS

Celldex Therapeutics
F. Hoffmann-La Roche Ltd.
Medac GmbH
MSD

SPONSORS SATELLITE SYMPOSIUM

Mundipharma Italy
Novocure
Sigma-Tau Pharmaceuticals Inc.

and the sponsors of the EORTC-EANO-ESMO Congress 2015 in Istanbul

KEY PARTNER

Novocure GmbH

EDUCATIONAL GRANT CONTRIBUTORS

Celldex Therapeutics
Roche

EDUCATIONAL GRANT SUPPORTER

Bristol-Myers Squibb